北美的动物用药市场 - 全球产业分析，规模，占有率，成长，趋势，预测(2031年)- 各产品，各动物类型，各终端用户，各国

北美动物用药市场近年来经历了稳定成长。这种扩张主要是由于宠物主人对动物健康的认识不断提高，以及对药物在治疗各动物种疾病方面发挥的重要作用的认识。预计该市场将持续呈上升趋势，2024年达到14.8亿美元，2031年达到27亿美元。

推动市场成长的主要因素是宠物主人对宠物健康的意识不断增强。根据美国宠物产品协会和美国兽医协会 (AVMA) 的报告，美国约有 8,490 万个家庭养宠物。越来越多的宠物主人增加了对兽医护理和针对其特定需求的复合药物的需求。

仿製药动物用药的高价格和容易取得也是促进市场扩张的因素。获得许可的药局为那些更喜欢这些药物而不是更昂贵的品牌药物的宠物主人提供了更实惠和更方便的选择。这种趋势在宠物照护费用过高的低收入家庭中尤其明显。

本报告提供北美的动物用药市场相关调查，提供市场概要，以及各产品，各动物类型，各终端用户，各国趋势，及市场参与市场企业的竞争趋势等资讯。

目录

第1章 摘要整理

第2章 市场概要

• 市场定义和市场区隔
• 市场动态
• 招聘率/使用情形分析- 主要统计
• 价值链分析
• 法规Scenario
• 产品的USP分析
• 波特的五力分析
• COVID-19影响分析
• 经济概要
• 大环境分析

第3章 北美的动物用药市场预测，2019年～2031年

• 北美的动物用药市场预测，各产品，金额(10亿美元)，2019年～2031年
• 北美的动物用药市场预测，各动物类型，金额(10亿美元)，2019年～2031年
• 北美的动物用药市场预测，各终端用户，金额(10亿美元)，2019年～2031年
• 北美的动物用药市场预测，各国，金额(10亿美元)，2019年～2031年

第4章 美国的动物用药市场预测，2019年～2031年

第5章 加拿大的动物用药市场预测，2019年～2031年

第6章 竞争情形

• 企业市场占有率分析，2023年
• 竞争仪表板
• 企业简介
  • Hoye's Pharmacy
  • Vertisis Custom Pharmacy
  • Smith Caldwell Drug Store
  • Sixth Avenue Medical Pharmacy
  • Dougherty Pharmacy
  • Triangle Compounding Pharmacy Inc.,
  • Wedgewood Pharmacy
  • Millers Pharmacy
  • Chiron Compounding Pharmacy
  • MEDS Canadian Compounding Pharmacy
  • Aurora Compounding
  • Pace Pharmacy

第7章 附录

The North American veterinary compounding pharmacies market has experienced robust growth in recent years. This expansion is largely driven by the increasing awareness among pet owners about animal health and the critical role of compounded medications in treating various conditions in animals. The market is expected to continue its upward trajectory, with a projected size of US$ 1.48 billion in 2024 and US$ 2.7 billion by 2031.

Key Drivers of Market Growth

Increasing Awareness and Pet Ownership

A primary factor propelling market growth is the heightened awareness of pet health among owners. Reports from the American Pet Product Association and the American Veterinary Medical Association (AVMA) indicate that nearly 84.9 million households in the U.S. own pets. This rise in pet ownership has led to a greater demand for veterinary care and compounded medications tailored to specific needs.

Cost and Availability of Generic Veterinary Drugs

The high cost and limited availability of generic veterinary drugs have also contributed to market expansion. Authorized compounding pharmacies provide more affordable and accessible options for pet owners, who often find these medications preferable to expensive branded drugs. This trend is especially notable in low-income households where the cost of animal care can be prohibitive.

Market Segmentation

CNS Agents Leading the Market

The CNS agents segment is anticipated to hold the largest market value, reaching approximately US$ 517.6 million in 2023. CNS medications are crucial for treating conditions such as attention deficit hyperactivity disorder (ADHD) in companion animals, particularly dogs, significantly contributing to market growth.

Companion Animals Dominate the Market

The companion animal segment, driven by the growing humanization of pets and increasing adoption rates, is expected to dominate the market. This segment is projected to hold around 58.7% of the market share.

Oral Formulations Preferred

Oral formulations are the most preferred method of drug administration in the veterinary sector due to their non-invasive nature, ease of administration, and patient compliance. This segment is expected to capture approximately 75.3% of the market share.

Regional Insights

U.S. Market Holds Significant Share

The U.S. is projected to maintain its dominance in the North American vet compounding pharmacies market, holding around 87.9% of the regional market share. The country's robust regulatory environment, expanding pharmaceutical sector, and increasing demand for diverse animal medications are key factors contributing to its leading position.

Canada's Growing Market Share

Canada is expected to hold a market share of around 12.1%. The increasing popularity of pet ownership and heightened awareness of animal healthcare are driving market growth in the country. Additionally, the introduction of new products by major players is bolstering the market.

Competitive Analysis

Leading companies in the North American vet compounding pharmacies market are focusing on expanding their customer base and enhancing their market presence through the development and launch of new and improved medications. The top four companies account for approximately 35.8% of the market share.

Key Developments

In January 2021, the FDA issued a recommendation titled GFI #256, outlining the conditions under which it would not enforce laws against the bulk manufacturing of medications. This recommendation supports the development of necessary antidotes for poisons found in animal food and significant differences between compounded medications and FDA-approved drugs with the same active ingredients.

In October 2020, Virbac introduced STELFONTA, a novel injectable treatment for canine mast cell tumors, the most common form of skin cancer in dogs. This treatment demonstrated a high rate of tumor eradication and marked a significant advancement in veterinary oncology.

Key Market Players Include:

Hoye's Pharmacy

Vertisis Custom Pharmacy

Smith Caldwell Drug Store

Sixth Avenue Medical Pharmacy

Dougherty Pharmacy

Triangle Compounding Pharmacy Inc.

Wedgewood Pharmacy

Millers Pharmacy

Chiron Compounding Pharmacy

MEDS Canadian Compounding Pharmacy

Aurora Compounding

Pace Pharmacy

Victoria Compounding Pharmacy

Pratt's Compounding Pharmacy

People's Choice Pharmacy

Global North America Vet Compounding Pharmacies Market Segmentation:

By Product:

CNS Agents

Anti-Infective Agents

Hormones and Substitutes

Anti-inflammatory Agents

Others

By Animal Type:

Companion Animals

Dogs

Cats

Equine

Others

Livestock Animals

By End User:

Oral

Injectable

Others

By Country:

U.S.

Canada

Table of Contents

1. Executive Summary

• 1.1. North America Vet Compounding Pharmacies Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Adoption Rate/Usage Analysis - Key Statistics
• 2.4. Value Chain Analysis
• 2.5. Regulatory Scenario
• 2.6. Product USP Analysis
• 2.7. Porter's Five Forces Analysis
• 2.8. COVID-19 Impact Analysis
  • 2.8.1. Supply
  • 2.8.2. Demand
• 2.9. Economic Overview
  • 2.9.1. World Economic Projections
• 2.10. PESTLE Analysis

3. North America Vet Compounding Pharmacies Market Outlook, 2019 - 2031

• 3.1. North America Vet Compounding Pharmacies Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. CNS Agents
    • 3.1.1.2. Anti-Infective Agents
    • 3.1.1.3. Hormones and Substitutes
    • 3.1.1.4. Anti-inflammatory Agents
    • 3.1.1.5. Others
• 3.2. North America Vet Compounding Pharmacies Market Outlook, by Animal Type, Value (US$ Bn), 2019 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Companion Animals
      • 3.2.1.1.1. Dogs
      • 3.2.1.1.2. Cats
      • 3.2.1.1.3. Equine
      • 3.2.1.1.4. Others
    • 3.2.1.2. Livestock Animals
• 3.3. North America Vet Compounding Pharmacies Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Oral
    • 3.3.1.2. Injectable
    • 3.3.1.3. Others
• 3.4. North America Vet Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. U.S.
    • 3.4.1.2. Canada

4. U.S. Vet Compounding Pharmacies Market Outlook, 2019 - 2031

• 4.1. U.S. Vet Compounding Pharmacies Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. CNS Agents
    • 4.1.1.2. Anti-Infective Agents
    • 4.1.1.3. Hormones and Substitutes
    • 4.1.1.4. Anti-inflammatory Agents
    • 4.1.1.5. Others
• 4.2. U.S. Vet Compounding Pharmacies Market Outlook, by Animal Type, Value (US$ Bn), 2019 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Companion Animals
      • 4.2.1.1.1. Dogs
      • 4.2.1.1.2. Cats
      • 4.2.1.1.3. Equine
      • 4.2.1.1.4. Others
    • 4.2.1.2. Livestock Animals
• 4.3. U.S. Vet Compounding Pharmacies Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Oral
    • 4.3.1.2. Injectable
    • 4.3.1.3. Others
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Canada Vet Compounding Pharmacies Market Outlook, 2019 - 2031

• 5.1. Canada Vet Compounding Pharmacies Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. CNS Agents
    • 5.1.1.2. Anti-Infective Agents
    • 5.1.1.3. Hormones and Substitutes
    • 5.1.1.4. Anti-inflammatory Agents
    • 5.1.1.5. Others
• 5.2. Canada Vet Compounding Pharmacies Market Outlook, by Animal Type, Value (US$ Bn), 2019 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Companion Animals
      • 5.2.1.1.1. Dogs
      • 5.2.1.1.2. Cats
      • 5.2.1.1.3. Equine
      • 5.2.1.1.4. Others
    • 5.2.1.2. Livestock Animals
• 5.3. Canada Vet Compounding Pharmacies Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Oral
    • 5.3.1.2. Injectable
    • 5.3.1.3. Others
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Competitive Landscape

• 6.1. Company Market Share Analysis, 2023
• 6.2. Competitive Dashboard
• 6.3. Company Profiles
  • 6.3.1. Hoye's Pharmacy
    • 6.3.1.1. Company Overview
    • 6.3.1.2. Product Portfolio
    • 6.3.1.3. Financial Overview
    • 6.3.1.4. Business Strategies and Development
  • 6.3.2. Vertisis Custom Pharmacy
    • 6.3.2.1. Company Overview
    • 6.3.2.2. Product Portfolio
    • 6.3.2.3. Financial Overview
    • 6.3.2.4. Business Strategies and Development
  • 6.3.3. Smith Caldwell Drug Store
    • 6.3.3.1. Company Overview
    • 6.3.3.2. Product Portfolio
    • 6.3.3.3. Financial Overview
    • 6.3.3.4. Business Strategies and Development
  • 6.3.4. Sixth Avenue Medical Pharmacy
    • 6.3.4.1. Company Overview
    • 6.3.4.2. Product Portfolio
    • 6.3.4.3. Financial Overview
    • 6.3.4.4. Business Strategies and Development
  • 6.3.5. Dougherty Pharmacy
    • 6.3.5.1. Company Overview
    • 6.3.5.2. Product Portfolio
    • 6.3.5.3. Financial Overview
    • 6.3.5.4. Business Strategies and Development
  • 6.3.6. Triangle Compounding Pharmacy Inc.,
    • 6.3.6.1. Company Overview
    • 6.3.6.2. Product Portfolio
    • 6.3.6.3. Financial Overview
    • 6.3.6.4. Business Strategies and Development
  • 6.3.7. Wedgewood Pharmacy
    • 6.3.7.1. Company Overview
    • 6.3.7.2. Product Portfolio
    • 6.3.7.3. Financial Overview
    • 6.3.7.4. Business Strategies and Development
  • 6.3.8. Millers Pharmacy
    • 6.3.8.1. Company Overview
    • 6.3.8.2. Product Portfolio
    • 6.3.8.3. Financial Overview
    • 6.3.8.4. Business Strategies and Development
  • 6.3.9. Chiron Compounding Pharmacy
    • 6.3.9.1. Company Overview
    • 6.3.9.2. Product Portfolio
    • 6.3.9.3. Financial Overview
    • 6.3.9.4. Business Strategies and Development
  • 6.3.10. MEDS Canadian Compounding Pharmacy
    • 6.3.10.1. Company Overview
    • 6.3.10.2. Product Portfolio
    • 6.3.10.3. Financial Overview
    • 6.3.10.4. Business Strategies and Development
  • 6.3.11. Aurora Compounding
    • 6.3.11.1. Company Overview
    • 6.3.11.2. Product Portfolio
    • 6.3.11.3. Financial Overview
    • 6.3.11.4. Business Strategies and Development
  • 6.3.12. Pace Pharmacy
    • 6.3.12.1. Company Overview
    • 6.3.12.2. Product Portfolio
    • 6.3.12.3. Financial Overview
    • 6.3.12.4. Business Strategies and Development

7. Appendix

• 7.1. Research Methodology
• 7.2. Report Assumptions
• 7.3. Acronyms and Abbreviations

List of Region/Countries

• North America
  • U.S.
  • Canada